Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23091728 | 1.00 | ABL1 (0.45) | ABL1TRPV1NAMPTLMNAMAPT | |
| SCHEMBL23091720 | 0.92 | ABL1 (0.46) | ABL1TRPV1NAMPTALDH1A1 | |
| SCHEMBL29687463 | 0.92 | ABL1 (0.46) | ABL1TRPV1NAMPTALDH1A1 | |
| SCHEMBL23091701 | 0.86 | TRPV1 (0.48) | ABL1TRPV1NAMPTMAPTFLT1 | |
| SCHEMBL23091646 | 0.84 | ABL1 (0.47) | ABL1TRPV1 | |
| SCHEMBL29687246 | 0.84 | ABL1 (0.47) | ABL1TRPV1 | |
| SCHEMBL24850296 | 0.83 | ABL1 (0.52) | ABL1TRPV1 | |
| SCHEMBL23091708 | 0.83 | TRPV1 (0.47) | ABL1TRPV1MAPTALDH1A1 | |
| SCHEMBL23091726 | 0.82 | RAB9A (0.44) | ABL1TRPV1ALDH1A1 | |
| SCHEMBL29687330 | 0.82 | RAB9A (0.44) | ABL1TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | claimed |
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | BenevolentAl Bio Limited (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4028387-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002346-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | ABL1 2/4885TRPV1 1085/4885NAMPT 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.